Samil Pharmaceutical Co.,Ltd (000520.KS)
KRW 13130.0
(-3.95%)
KRW 13130.0
(-3.95%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 72.21 Billion KRW | 7.0% |
| 2022 | 67.48 Billion KRW | 37.76% |
| 2021 | 48.98 Billion KRW | -0.09% |
| 2020 | 49.03 Billion KRW | 4.94% |
| 2019 | 46.72 Billion KRW | 34.3% |
| 2018 | 34.79 Billion KRW | -14.95% |
| 2017 | 40.9 Billion KRW | -1.31% |
| 2016 | 41.45 Billion KRW | 10.98% |
| 2015 | 37.34 Billion KRW | 9.93% |
| 2014 | 33.97 Billion KRW | -5.98% |
| 2013 | 36.13 Billion KRW | -4.31% |
| 2012 | 37.76 Billion KRW | -0.98% |
| 2011 | 38.13 Billion KRW | -12.11% |
| 2010 | 43.38 Billion KRW | 14.88% |
| 2009 | 37.76 Billion KRW | -32.25% |
| 2008 | 55.74 Billion KRW | 14.35% |
| 2007 | 48.74 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 20.62 Billion KRW | 9.42% |
| 2024 Q1 | 19.3 Billion KRW | -1.06% |
| 2023 FY | 72.21 Billion KRW | 7.0% |
| 2023 Q4 | 19.51 Billion KRW | 8.95% |
| 2023 Q2 | 18.71 Billion KRW | 7.1% |
| 2023 Q1 | 17.47 Billion KRW | 10.24% |
| 2023 Q3 | 17.9 Billion KRW | -4.3% |
| 2022 Q4 | 15.85 Billion KRW | -6.32% |
| 2022 FY | 67.48 Billion KRW | 37.76% |
| 2022 Q2 | 17.48 Billion KRW | 1.44% |
| 2022 Q3 | 16.92 Billion KRW | -3.21% |
| 2022 Q1 | 17.23 Billion KRW | 43.17% |
| 2021 Q2 | 12.37 Billion KRW | 1.21% |
| 2021 Q3 | 12.35 Billion KRW | -0.17% |
| 2021 Q1 | 12.22 Billion KRW | 9.13% |
| 2021 FY | 48.98 Billion KRW | -0.09% |
| 2021 Q4 | 12.03 Billion KRW | -2.56% |
| 2020 Q3 | 12.25 Billion KRW | 1.18% |
| 2020 FY | 49.03 Billion KRW | 4.94% |
| 2020 Q1 | 13.46 Billion KRW | 23.02% |
| 2020 Q2 | 12.11 Billion KRW | -10.02% |
| 2020 Q4 | 11.2 Billion KRW | -8.58% |
| 2019 Q3 | 11.46 Billion KRW | -2.97% |
| 2019 Q4 | 10.94 Billion KRW | -4.56% |
| 2019 Q2 | 11.81 Billion KRW | -5.48% |
| 2019 Q1 | 12.5 Billion KRW | 53.83% |
| 2019 FY | 46.72 Billion KRW | 34.3% |
| 2018 Q3 | 8.46 Billion KRW | -12.1% |
| 2018 FY | 34.79 Billion KRW | -14.95% |
| 2018 Q4 | 8.12 Billion KRW | -3.99% |
| 2018 Q2 | 9.62 Billion KRW | 12.34% |
| 2018 Q1 | 8.57 Billion KRW | -20.53% |
| 2017 FY | 40.9 Billion KRW | -1.31% |
| 2017 Q3 | 8.37 Billion KRW | -21.0% |
| 2017 Q4 | 10.78 Billion KRW | 28.84% |
| 2017 Q2 | 10.59 Billion KRW | -4.97% |
| 2017 Q1 | 11.15 Billion KRW | 4.09% |
| 2016 Q1 | 10.2 Billion KRW | 14.38% |
| 2016 Q4 | 10.71 Billion KRW | 9.98% |
| 2016 FY | 41.45 Billion KRW | 10.98% |
| 2016 Q3 | 9.74 Billion KRW | -9.71% |
| 2016 Q2 | 10.78 Billion KRW | 5.66% |
| 2015 Q1 | 10.57 Billion KRW | 48.52% |
| 2015 Q4 | 8.92 Billion KRW | -3.25% |
| 2015 Q3 | 9.22 Billion KRW | 7.0% |
| 2015 Q2 | 8.62 Billion KRW | -18.46% |
| 2015 FY | 37.34 Billion KRW | 9.93% |
| 2014 Q3 | 8.03 Billion KRW | -14.96% |
| 2014 Q4 | 7.12 Billion KRW | -11.39% |
| 2014 FY | 33.97 Billion KRW | -5.98% |
| 2014 Q1 | 9.37 Billion KRW | 16.61% |
| 2014 Q2 | 9.44 Billion KRW | 0.84% |
| 2013 Q4 | 8.03 Billion KRW | -3.99% |
| 2013 Q1 | 9.73 Billion KRW | 12.69% |
| 2013 Q2 | 9.99 Billion KRW | 2.63% |
| 2013 FY | 36.13 Billion KRW | -4.31% |
| 2013 Q3 | 8.36 Billion KRW | -16.25% |
| 2012 Q3 | 9.52 Billion KRW | -14.66% |
| 2012 Q4 | 8.64 Billion KRW | -9.24% |
| 2012 FY | 37.76 Billion KRW | -0.98% |
| 2012 Q1 | 8.06 Billion KRW | 0.0% |
| 2012 Q2 | 11.15 Billion KRW | 38.32% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 38.13 Billion KRW | -12.11% |
| 2011 Q3 | 9.27 Billion KRW | -11.87% |
| 2011 Q2 | 10.52 Billion KRW | -3.62% |
| 2011 Q1 | 10.92 Billion KRW | -2.04% |
| 2010 FY | 43.38 Billion KRW | 14.88% |
| 2010 Q3 | 10.18 Billion KRW | -15.33% |
| 2010 Q4 | 11.14 Billion KRW | 9.5% |
| 2010 Q2 | 12.02 Billion KRW | 19.81% |
| 2010 Q1 | 10.03 Billion KRW | 11.87% |
| 2009 Q4 | 8.97 Billion KRW | -10.17% |
| 2009 Q1 | 9.47 Billion KRW | -0.6% |
| 2009 Q3 | 9.98 Billion KRW | 6.97% |
| 2009 Q2 | 9.33 Billion KRW | -1.46% |
| 2009 FY | 37.76 Billion KRW | -32.25% |
| 2008 Q1 | 16.57 Billion KRW | 101.19% |
| 2008 Q3 | 12 Billion KRW | -31.93% |
| 2008 FY | 55.74 Billion KRW | 14.35% |
| 2008 Q2 | 17.63 Billion KRW | 6.36% |
| 2008 Q4 | 9.53 Billion KRW | -20.58% |
| 2007 Q1 | 13.78 Billion KRW | 0.0% |
| 2007 Q2 | 13.67 Billion KRW | -0.76% |
| 2007 Q3 | 12.47 Billion KRW | -8.76% |
| 2007 FY | 48.74 Billion KRW | 0.0% |
| 2007 Q4 | 8.24 Billion KRW | -33.96% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -55.277% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 80.168% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 63.692% |
| HANDOK Inc. | 151.36 Billion KRW | 52.294% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -7.418% |
| Yuhan Corporation | 564.5 Billion KRW | 87.208% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 77.589% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -204.086% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 91.361% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | 3.769% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 63.706% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -77.644% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | 23.598% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | 48.734% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -55.277% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -108.008% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | 5.997% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 699.484% |
| JW Holdings Corporation | 446.15 Billion KRW | 83.815% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 65.206% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 88.981% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 78.487% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 8.151% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | 4.023% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | 60.715% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -55.277% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 75.531% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 89.405% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 78.487% |
| Yuhan Corporation | 564.5 Billion KRW | 87.208% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 64.22% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -1.794% |
| Suheung Co., Ltd. | 99.02 Billion KRW | 27.079% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 78.487% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | 50.503% |
| Korea United Pharm Inc. | 173.48 Billion KRW | 58.377% |
| CKD Bio Corp. | 5.01 Billion KRW | -1341.262% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 71.596% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 60.781% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | 26.409% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 8.151% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 80.562% |
| Boryung Corporation | 333.26 Billion KRW | 78.332% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -44.292% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 63.706% |
| JW Lifescience Corporation | 51.32 Billion KRW | -40.695% |